Literature DB >> 31594651

Pathophysiology of the irritable bowel syndrome - Reflections of today.

Per M Hellström1.   

Abstract

Irritable bowel syndrome (IBS) is a chronic gastrointestinal symptom complex defined by abdominal pain and disturbed bowel habits over 3 months within a period of 6 months, in absence of any identifiable organic pathology. Over the years, speculations of the pathophysiology of IBS has moved from elusive central nervous symptoms impinging on psychosomatic disease, to objective signs of intestinal fermentation with abdominal bloating and intestinal dysmotility. The specific subgroup of post-infectious IBS is of special interest since it opens the possibility of dysbiosis as the pivotal point for development of IBS in association with traveler's diarrhea or antibiotic treatment with ensuing dysbiosis and abdominal symptoms that may resolve over decades. The undefined disease mechanisms that take place within the gut seem responsible for the gut-brain signaling leading to activation of brain centers that drive the clinical picture of IBS, further modulated by the patient's social background and previous lifetime events.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Dysbiosis; Irritable bowel syndrome; Motility; Rectal distension; Serotonin

Mesh:

Year:  2019        PMID: 31594651     DOI: 10.1016/j.bpg.2019.05.007

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  7 in total

Review 1.  Functional bowel symptoms in the general population (Review).

Authors:  Bodil Ohlsson
Journal:  Mol Med Rep       Date:  2022-05-20       Impact factor: 3.423

Review 2.  Enlightening the frontiers of neurogastroenterology through optogenetics.

Authors:  Anthony C Johnson; Tijs Louwies; Casey O Ligon; Beverley Greenwood-Van Meerveld
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-08-05       Impact factor: 4.052

Review 3.  Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals?

Authors:  Vicente Martínez; Amaia Iriondo De-Hond; Francesca Borrelli; Raffaele Capasso; María Dolores Del Castillo; Raquel Abalo
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

Review 4.  Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome.

Authors:  Minjia Chen; Guangcong Ruan; Lu Chen; Senhong Ying; Guanhu Li; Fenghua Xu; Zhifeng Xiao; Yuting Tian; Linling Lv; Yi Ping; Yi Cheng; Yanling Wei
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-16       Impact factor: 5.555

5.  Upregulated adenosine 2A receptor accelerates post-infectious irritable bowel syndrome by promoting CD4+ T cells' T helper 17 polarization.

Authors:  Li-Wei Dong; Zhi-Chao Ma; Jiao Fu; Bai-Li Huang; Fu-Jin Liu; Deming Sun; Cheng Lan
Journal:  World J Gastroenterol       Date:  2022-07-07       Impact factor: 5.374

Review 6.  Molecular Mechanisms of Microbiota-Mediated Pathology in Irritable Bowel Syndrome.

Authors:  Yoshiyuki Mishima; Shunji Ishihara
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

Review 7.  Role of gut microbiota via the gut-liver-brain axis in digestive diseases.

Authors:  Jian-Hong Ding; Zhe Jin; Xiao-Xu Yang; Jun Lou; Wei-Xi Shan; Yan-Xia Hu; Qian Du; Qiu-Shi Liao; Rui Xie; Jing-Yu Xu
Journal:  World J Gastroenterol       Date:  2020-10-28       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.